Clinical Trial Update: Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]

View source ↗

Summary

Phase 1 safety study of repeated dosing with a cytotoxic lymphocyte–based therapy for hormone-refractory prostate cancer, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CTL-based Prostate Cancer Therapy

Snippet

Sponsor: CytoVac A/S | Conditions: Hormone-refractory Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2014-04-23